Answer: Different types of drugs affect your body in different ways, and the effects associated with drugs can vary from person to person. How a drug effects an individual is dependent on a variety of factors including body size, general health, the amount and strength of the drug, and whether any other drugs are in the system at the same time. It is important to remember that illegal drugs are not controlled substances, and therefore the quality and strength may differ from one batch to another
Explanation:
Answer: HDLs are antiatherogenic lipoproteins....
Explanation:
The anti-atherogenic effect of HDL occurs, above all, because of its properties to carry lipids, mainly cholesterol esters from peripheral tissues to the liver, which is known as reverse cholesterol transport(RCT). However, other protective actions of HDL, in addition to RCT, have been described in several experimental models and epidemiological studies. These actions include antioxidant protection, mediation of cholesterol efflux, inhibition of the expression of cell adhesion, leukocyte activation, regulation of blood coagulation and platelet activity.
I would say it is a mixture of all the above! The moral to the story is never trust or rely on anyone but yourself at the end of the day.
Answer:
b) blastic red blood cell (RBC).
Explanation:
In excess of 340 blood group antigens have now been described that vary between individuals. Thus, any unit of blood that is nonautologous represents a significant dose of alloantigen. Most blood group antigens are proteins, which differ by a single amino acid between donors and recipients. Approximately 1 out of every 70 individuals are transfused each year (in the United States alone), which leads to antibody responses to red blood cell <u>(RBC) alloantigens</u> in some transfusion recipients. When alloantibodies are formed, in many cases, RBCs expressing the antigen in question can no longer be safely transfused. However, despite chronic transfusion, only 3% to 10% of recipients (in general) mount an alloantibody response. In some disease states, rates of alloimmunization are much higher (eg, sickle cell disease). For patients who become alloimmunized to multiple antigens, ongoing transfusion therapy becomes increasingly difficult or, in some cases, impossible. While alloantibodies are the ultimate immune effector of humoral alloimmunization, the cellular underpinnings of the immune system that lead to ultimate alloantibody production are complex, including antigen consumption, antigen processing, antigen presentation, T-cell biology.
The cervix is superior to the vagina
